Researchers have developed and preliminarily tested a composite score that simultaneously assesses the severity of asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in patients with both ...

SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared ...

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD: Paris Wednesday, April 16, 2025, 10:00 Hrs [IST] Sanofi shared new pro ...

Sanofi added that, in partnership with Regeneron, two phase 3 studies in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), CEREN 1 and CEREN 2 and one phase 2 study in patients with ...

Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthmaLunsekimig ...

Itepekimab: expanding clinical studies beyond COPD into chronic rhinosinusitis In partnership with Regeneron, two phase 3 studies in patients with chronic rhinosinusitis with nasal polyps (CRSwNP ...

AZ is hoping that Fasenra (benralizumab) could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as approved therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) that have been ...